Literature DB >> 6468624

The bisphosphonates HEBP and AHPrBP but not AHBP inhibit mineral mobilization and lysosomal enzyme release from mouse calvarial bones in tissue culture.

U Lerner, A Larsson.   

Abstract

The effect of 3 bisphosphonates, 1-hydroxyethylidene-1, 1-bisphosphonate (HEBP), 3-amino-1-hydroxy-propylidene-1, 1-bisphosphonate (AHPrBP) and azacycloheptylidene-2, 2-bisphosphonate (AHBP), on the release of minerals (40Ca, 45Ca, Pi) and enzymes from cultured mouse calvaria was investigated in an organ culture system. HEBP and AHPrBP reduced PTH-stimulated mobilization of calcium and inorganic phosphate without affecting the release of lactate dehydrogenase. In contrast, no significant effect by AHBP on mineral mobilization and lysosomal enzyme release could be registered. In parallel with inhibited mineral mobilization, HEBP and AHPrBP inhibited the release of the lysosomal enzyme beta-glucuronidase. A possible cellular mechanism of action of bisphosphonates is discussed in the light of these data.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6468624     DOI: 10.1007/bf01946461

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  13 in total

1.  Studies on bone enzymes. The assay of acid hydrolases and other enzymes in bone tissue.

Authors:  G Vaes; P Jacques
Journal:  Biochem J       Date:  1965-11       Impact factor: 3.857

2.  Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  W B Frijlink; O L Bijvoet; J te Velde; G Heynen
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

Review 3.  Experimental basis for the clinical use of diphosphonates in Paget's disease of bone.

Authors:  H Fleisch
Journal:  Arthritis Rheum       Date:  1980-10

4.  APD in Paget's disease of bone. Role of the mononuclear phagocyte system?

Authors:  O L Bijvoet; W B Frijlink; K Jie; H van der Linden; C J Meijer; H Mulder; H C van Paassen; P H Reitsma; J te Velde; E de Vries; J P van der Wey
Journal:  Arthritis Rheum       Date:  1980-10

5.  Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).

Authors:  R D Altman; C C Johnston; M R Khairi; H Wellman; A N Serafini; R R Sankey
Journal:  N Engl J Med       Date:  1973-12-27       Impact factor: 91.245

6.  Inhibitory effect of dibutyryl cyclic AMP on the release of calcium, inorganic phosphate and lysosomal enzymes from calvarial bones cultured for 24 hours.

Authors:  U Lerner; G T Gustafson
Journal:  Acta Endocrinol (Copenh)       Date:  1979-08

7.  Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

Authors:  P H Reitsma; O L Bijvoet; M Potokar; L J van der Wee-Pals; M M van Wijk-van Lennep
Journal:  Calcif Tissue Int       Date:  1983-05       Impact factor: 4.333

8.  Diphosphonate therapy of paget's disease of bone.

Authors:  R Canfield; W Rosner; J Skinner; J McWhorter; L Resnick; F Feldman; S Kammerman; K Ryan; M Kunigonis; W Bohne
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

9.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

10.  Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.

Authors:  D L Douglas; T Duckworth; R G Russell; J A Kanis; C J Preston; F E Preston; M A Prenton; J S Woodhead
Journal:  Lancet       Date:  1980-05-17       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.